Patrizia Giannatempo/VJOncology.org
Sep 19, 2024, 07:37
Patrizia Giannatempo: The benefit of adjuvant pembrolizumab with extended follow-up 45 months
Patrizia Giannatempo shared a post on X:
“The AMBASSADOR trial confirms the benefit of adjuvant pembrolizumab with extended fu 45 months:
- regardless of PD-L1 status
- lower tract.
Andrea Apolo – exceptional as always.”
Source: Patrizia Giannatempo/X
Patrizia Giannatempo is a Medical Oncology Consultant specializing in urological cancers at the National Cancer Institute (INT) in Milan, Italy. She serves as the principal investigator for several academic trials focused on urothelial, testicular, and penile cancers.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 1, 2025, 19:24
Aug 1, 2025, 19:14
Aug 1, 2025, 18:32